Search Results - Aram Oganesian

Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study by Klaus Geissler, Zdenek Koristek, Teresa Bernal del Castillo, Jan Novák, Gabriela Rodríguez‐Macías, Stephan K. Metzelder, Arpad Illes, Jiří Mayer, Montserrat Arnan, Mary‐Margaret Keating, Jürgen Krauter, Monia Lunghi, Nicola Stefano Fracchiolla, Uwe Platzbecker, Valeria Santini, Yuri Sano, Aram Oganesian, Harold Keer, Michael Lübbert

Get full text

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies by Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Harshad Amin, Amy E. DeZern, Elizabeth A. Griffiths, Kim‐Hien Dao, Amer M. Zeidan, Bhavana Bhatnagar, Rena Buckstein, Brian Leber, Mary‐Margaret Keating, Somedeb Ball, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia‐Manero

Get full text

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs by Wei Gao, Jiang Liu, Cynthia J. Musante, Hao Zhu, Matthew Thompson, Mirat Shah, Yanguang Cao, Vijay Ivaturi, Mark R. Conaway, Dean Bottino, Donghua Yin, Dorothee Semiond, Aram Oganesian, Mark J. Ratain, Chunze Li, Li Zhu, Ying C. Ou, Xiling Jiang, Jonathan Vallejo, Rajanikanth Madabushi, Qi Liu, Marc Theoret, Atiqur Rahman, Brian Booth, Olanrewaju Okusanya, Bernadette E. Johnson‐Williams, Stacy S. Shord

Get full text